FDA Approves GABAPENTIN — ScieGen Pharmaceuticals, Inc.

# FDA Approves ScieGen Pharmaceuticals' Generic Gabapentin ScieGen Pharmaceuticals, Inc. received FDA approval for its generic gabapentin oral formulation, marking another entry into the competitive neurological medication market and intensifying pricing pressure on branded alternatives. The approval of ScieGen's gabapentin is expected to expand treatment accessibility and drive down costs for patients requiring this widely-used pain and seizure management therapy.